Analysis Group Consultants Publish Article on Pneumonia Treatment Efficacy/Safety Trade-Offs
February 9, 2017
Community-acquired pneumonia (CAP), one of the most common infectious diseases and a significant cause of death worldwide, is treated with a number of different antibiotic regimens — but perhaps not with an ideal one. According to new research by Analysis Group Managing Principal Edward Tuttle and Associate Christopher Llop, the leading medication classes “often present a trade-off between the potential for treatment failure and safety concerns.” Along with coauthors Glenn S. Tillotson, Kerry LaPlante, and Thomas M. File, Jr., as well as a supporting team of Analysis Group health care specialists, Mr. Tuttle and Mr. Llop analyzed the medical records data of nearly half a million patients treated for CAP between 2007 and 2012. The authors determined that the therapeutic class of fluoroquinolones displayed the highest efficacy and resulted in shorter hospital stays (and, consequently, significant cost savings) when compared with other therapies that are recommended in current US guidelines. However, this class of drug also led to a much higher likelihood of adverse events.
The group's findings were published in the article “Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study” (Hospital Practice, January 18, 2017).